UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-Q

(Mark One)
    [ x ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

              For the quarterly period ended October 31, 2009
                                             ----------------

                                       or

    [  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
                              EXCHANGE ACT OF 1934

            For the transition period from       to
                                           ----     ----

                       Commission file number 333-139915
                                              ----------

                          LIGHTLAKE THERAPEUTICS INC.
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)


                Nevada                                          N/A
--------------------------------------------------------------------------------
     (State or other jurisdiction                  (IRS Employer Identification
   of incorporation or organization)                          No.)



            54 Baker Street., 6th Floor                       W1U 7BU
--------------------------------------------------------------------------------
            (Address of principal executive offices)     (Zip Code)

                                44-207-034-1943
--------------------------------------------------------------------------------
              (Registrant's telephone number, including area code)

--------------------------------------------------------------------------------
   (Former name, former address and former fiscal year, if changed since last
                                    report)

     Indicate  by  check  mark  whether the registrant (1) has filed all reports
required  to  be filed by Section 13 or 15(d) of the Exchange Act of 1934 during
the  preceding  12  months  (or  for such shorter period that the registrant was
required  to  file  such  reports),  and  (2)  has  been  subject to such filing
requirements  for  the  past  90  days.
                                                Yes      [X]         No      [ ]

     Indicate by check mark whether the registrant is a large accelerated filer,
an  accelerated  filer, a non-accelerated filer, or a smaller reporting company.
See  the  definitions  of  "large  accelerated  filer,"  "accelerated filer" and
"smaller  reporting  company"  in  Rule  12b-2  of  the  Exchange  Act.

Large accelerated filer     [ ]          Accelerated filer             [ ]

Non-accelerated filer       [ ]          Smaller reporting company     [X]
(Do not check if a smaller
reporting company)

     Indicate by check mark whether the registrant is a shell company (as
defined in Rule 12b-2 of the Exchange Act).
                                                 Yes    [ ]            No    [X]

               APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                  PROCEEDINGS DURING THE PRECEDING FIVE YEARS

     Indicate  by  check mark whether the registrant has filed all documents and
reports  required  to  be  filed  by  Sections 12, 13 or 15(d) of the Securities
Exchange  Act  of 1934 subsequent to the distribution of securities under a plan
confirmed  by  a  court.
                                                 Yes    [ ]             No   [ ]

<PAGE>
                      APPLICABLE ONLY TO CORPORATE ISSUERS

     The were 157,658,333 shares of Common Stock outstanding as of October 31,
2009:


                         PART I - FINANCIAL INFORMATION

Item 1. Financial Statements.

<TABLE>
<CAPTION>
<S>                                                                 <C>               <C>
Lightlake Therapeutics, Inc.
(Formerly Known as Madrona Ventures, Inc.)
Balance Sheet
October 31, 2009 and July 31, 2009
-------------------------------------------------------------------------------------------------------
                                                                        October 31,        July 31,
Assets                                                                     2009              2009
                                                                      ---------------  ----------------
Current assets
  Cash and cash equivalents                                           $          724   $           290
  Other current assets                                                             -                 -
                                                                      ---------------  ----------------
     Total current assets                                                        724               290

Other assets
  Patent and Patent Applications                                              20,333                 -
                                                                      ---------------  ----------------

     Total assets                                                     $       21,057   $           290
                                                                      ===============  ================

        Liabilities and Shareholders' Deficit
Liabilities
  Accounts payable and accrued liabilities                            $        1,100   $             -
  Due to related party                                                        75,248                 -
                                                                      ---------------  ----------------
    Total liabilities                                                         76,348                 -


Stockholders' equity (deficit)
  Common stock; par value $0.001; 200,000,000 shares authorized;
    157,658,333 shares issued and outstanding at October 31, 2009 and
      6,525,000 shares issued and outstanding at October 31, 2008            157,658             6,525
  Additional paid-in capital                                                 (81,525)           48,975
  Accumulated deficit during the development stage                          (131,424)          (55,210)
                                                                      ---------------  ----------------
    Total stockholders' deficit                                              (55,291)              290
                                                                      ---------------  ----------------
     Total liabilities and stockholders' equity                       $       21,057   $           290
                                                                      ===============  ================
</TABLE>

     The accompanying notes are an integral part of these financial statements.

                                       2
<PAGE>

<TABLE>
<CAPTION>
<S>                                    <C>                   <C>                    <C>
Lightlake Therapeutics, Inc.
(Formerly Known as Madrona Ventures, Inc.)
Statements of Operations
For the Three Months Ended October 31, 2009 and 2008 and the Period From
 Inception (June 21, 2005) to October 31, 2009
----------------------------------------------------------------------------------------------------------

                                                                                        From Inception
                                                                                        (June 21, 2005)
                                             Three Months Ended - October 31,           to October 31,
                                                2009                  2008                   2009
                                        --------------------  ---------------------  ---------------------

Revenues                                $                 -   $                  -   $                  -

Operating expenses
 General and administrative                          76,214                  5,372                135,572
 Mineral interests                                        -                      -                 39,015
                                        --------------------  ---------------------  ---------------------
  Total operating expenses                           76,214                  5,372                174,587
                                        --------------------  ---------------------  ---------------------

Income (loss) from operations                       (76,214)                (5,372)              (174,587)

Other income (expense)
 Debt forgiveness                                         -                      -                 43,163
                                        --------------------  ---------------------  ---------------------
  Total other income (expense)                            -                      -                 43,163

Income (loss) before provision for
 income taxes                                       (76,214)                (5,372)              (131,424)

Provision for income taxes                                -                      -                      -
                                        --------------------  ---------------------  ---------------------

Net income (loss)                       $           (76,214)  $             (5,372)  $           (131,424)
                                        ====================  =====================  =====================

Basic and fully diluted loss per
 common share:
 Earnings (loss) per common share       $             (0.00)  $              (0.00)
                                        ====================  =====================
Basic and fully diluted weighted average
 common shares outstanding                       94,449,311              6,525,000
                                        ====================  =====================
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                       3
<PAGE>

<TABLE>
<CAPTION>
<S>                              <C>         <C>        <C>         <C>           <C>
Lightlake Therapeutics, Inc.
(Formerly Known as Madrona Ventures, Inc.)
Statement of Changes in Stockholders' Equity (Deficit)
For the Three Months Ended October 31, 2009 and Year Ended July 31, 2009 and
the Period from Inception (June 21, 2005) to October 31, 2009
----------------------------------------------------------------------------------------------

                                                                       Deficit
                                                        Additional   During the
                                      Common Stock        Paid In    Development
                                   Shares      Amount     Capital       Stage        Total
                                 ----------- ---------- ----------- ------------- ------------
Balance at June 21, 2005                   - $        - $        -  $          -  $         -
                                 ----------- ---------- ----------- ------------- ------------

Balance at July 31, 2005                   -          -          -             -            -
                                 ----------- ---------- ----------- ------------- ------------

Common shares issued for cash
  March 2006 at $0.001 per share   5,000,000      5,000          -                      5,000
  March 2006 at $0.01 per share    1,300,000      1,300     11,700                     13,000
  April 2006 at $0.01 per share       75,000         75      7,425                      7,500
  May 2006 at $0.01 per share        150,000        150     29,850                     30,000

Net income (loss)                                                        (32,125)     (32,125)
                                 ----------- ---------- ----------- ------------- ------------

Balance at July 31, 2006           6,525,000      6,525     48,975       (32,125)      23,375

Net income (loss)                                                        (33,605)     (33,605)
                                 ----------- ---------- ----------- ------------- ------------

Balance at July 31, 2007           6,525,000      6,525     48,975       (65,730)     (10,230)

Net income (loss)                                                        (17,924)     (17,924)
                                 ----------- ---------- ----------- ------------- ------------

Balance at July 31, 2008           6,525,000      6,525     48,975       (83,654)     (28,154)

Net income (loss)                          -          -          -        28,444       28,444
                                 ----------- ---------- ----------- ------------- ------------

Balance at July 31, 2009           6,525,000 $    6,525 $   48,975  $    (55,210) $       290

Forward Stock Split : 20 for 1   130,500,000 $  130,500 $ (130,500)                         -

Stock Issued for Services            300,000        300          -              -         300

Stock Issued for Acquisition of
 Patent                           20,333,333     20,333          -              -      20,333

Net income (loss)                                                        (76,214)     (76,214)
                                 ----------- ---------- ----------- ------------- ------------

Balance at October 31, 2009      157,658,333 $  157,658 $  (81,525) $   (131,424) $   (55,291)
                                 =========== ========== =========== ============= ============
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                       4
<PAGE>

<TABLE>
<CAPTION>
<S>                                               <C>             <C>                <C>
Lightlake Therapeutics, Inc.
(Formerly Known as Madrona Ventures, Inc.)
Statements of Cash Flows
For the Three Months Ended October 31, 2009 and Year Ended July 31, 2009 and the Period From
Inception (June 21, 2005) to October 31, 2009
-----------------------------------------------------------------------------------------------------------

                                                                                         From Inception
                                                                                        (June 21, 2005)
                                                  Three Months Ended - October 31,       to October 31,
                                                        2009             2008                 2009
                                                ------------------ ----------------- ----------------------

Cash Flows Provided (Used) By Operating Activities
 Net income (loss)                                 $      (76,214) $         (5,372) $            (131,424)
 Adjustments to reconcile net income (loss) to net cash
  provided from (used by) operating activities:
   Increase (decrease) in accounts payable                  1,100            (4,045)                 1,100
   Increase (decrease) in due to related party             75,248             9,218                 75,248
                                                ------------------ ----------------- ----------------------
    Net cash provided from (used by) operating
     activities                                               134              (199)               (55,076)

Cash Flows Provided (Used) By Investing
 Activities                                                     -                 -                      -

Cash Flows Provided (Used) By Financing Activities
 Issuance of common stock for services                        300                                      300
 Issuance of common stock for cash                              -                 -                 55,500
                                                ------------------ ----------------- ----------------------
  Net cash provided from (used by) financing
   activities                                                 300                 -                 55,800

Net increase (decrease) in cash and cash
 equivalents                                                  434              (199)                   724
Cash and cash equivalents, beginning of year                  290               206                      -
                                                ------------------ ----------------- ----------------------
Cash and cash equivalents, end of year             $          724  $              7  $                 724
                                                ================== ================= ======================

Supplemental disclosure
 Interest paid during the period                   $            -  $              -  $                   -
                                                ================== ================= ======================

Non-Cash Transactions
 In August, 2009, the Company acquired a Patent and Patent Applications through
 the issuance of 20,333,000 Common shares.
</TABLE>

   The accompanying notes are an integral part of these financial statements.

                                       5
<PAGE>

Lightlake Therapeutics, Inc.
(Formerly Known As Madrona Ventures, Inc.)
Notes to Financial Statements
October 31, 2009
--------------------------------------------------------------------------------

1.   Organization, Description of Business, and Basis of Accounting

     Business Organization

     Lightlake Therapeutics, Inc,. (formerly known as Madrona Ventures, Inc.)
     (the Company) was originally incorporated in the State of Nevada on June
     21, 2005. On September 16, 2009, the Company changed its' name to Lightlake
     Therapeutics, Inc. The Company's fiscal year end is July 31. The company is
     currently in the development stage and to date its' activities have been
     limited to capital formation. The Company has limited assets and no revenue
     and in accordance with SFAS No.7, is considered a Development Stage
     Company.

     Accounting Basis
     Interim Financial Statements

     The accompanying unaudited condensed consolidated financial statements have
     been prepared in accordance with accounting principles generally accepted
     in the United States of America, pursuant to the rules and regulations of
     the Securities and Exchange Commission. All significant intercompany
     balances and transactions have been eliminated. These financial statements
     do not include all information and notes required by accounting principles
     generally accepted in the United States of America for complete financial
     statements. It is recommended that these interim unaudited condensed
     consolidated financial statements be read in conjunction with the
     consolidated financial statements and notes thereto included in the
     Company's Annual Report on Form 10-K for the fiscal year ended July 31,
     2009.

     In the opinion of management, all adjustments (consisting only of normal
     recurring accruals) considered necessary for a fair presentation have been
     included. Operating results for the nine month period ended June 30, 2009
     are not necessarily indicative of the results which may be expected for any
     other interim periods or for the year ending September 30, 2010. The
     preparation of financial statements in conformity with accounting
     principles generally accepted in the United States of America requires
     management to make estimates and assumptions that affect the reported
     amounts of assets and liabilities and disclosure of contingent assets and
     liabilities at the date of the financial statements and the reported
     amounts of revenues and expenses during the reporting period. Actual
     results could differ from these estimates.

2.   Patent and Patent Applications

     On August 24, 2009, the Company acquired European Patent EP1681057B1 and
     U.S. Patent Application 11/031,534 through the issuance of 20,333,000 of
     its' common stock.


3.   Going Concern

     The accompanying financial statements have been prepared assuming the
     Company will continue as a going concern, which contemplates the
     realization of assets and the liquidation of liabilities in the normal
     course of business. This raises substantial doubt about the Company's
     ability to continue as a going concern. These financial statements do not
     include any adjustments that might result from this uncertainty

                                       6
<PAGE>

Lightlake Therapeutics, Inc.
(Formerly Known As Madrona Ventures, Inc.)
Notes to Financial Statements
October 31, 2009
--------------------------------------------------------------------------------

4.   Capital Stock

     The Company has 200,000,000 common shares authorized at a par value of
     $0.001. At October 31, 2009, there were 157,658,333 shares issued and
     outstanding. The Company has no other classes of shares authorized for
     issuance.

     At October 31, 2009, there were no outstanding stock options or warrants.

5.   Common Stock Purchase Agreement

     On October 31, 2009, the Company completed a common stock purchase
     agreement (the Pelikin Agreement) whereby Pelikin Group acquired 5,000,000
     common shares of the Company's common stock from Belmont Partners.
     Following the transaction, Pelikin Group controls approximately 76.6% of
     the Company's outstanding capital stock. Concurrent with the agreement, Mr.
     Sei Ki was named to the Board of Directors as well as President and
     Secretary of the Company, and Mr. Joseph Muese resigned from all positions
     held in the Company.

6.   Income Taxes

     The Company has net operating loss carryforwards that were derived solely
     from operating losses from prior years. These amounts can be carried
     forward to offset future taxable income for a period of 20 years for each
     tax year's loss. No provision was made for federal income taxes as the
     Company has significant net operating losses.

     The operating losses derive a deferred tax asset of approximately $30,277
     and $18,800 at October 31, 2009 and July 31, 2008, respectively. At October
     31, and July 31,2009, the Company has established a valuation allowance
     equal to the deferred tax assets as there is no assurance that the Company
     will generate future taxable income to utilize these assets.

     Due to the provisions of Internal Revenue Code Section 338, the Company may
     have no net operating loss carryforwards available to offset financial
     statement or tax return taxable income in future periods as a result of a
     change in control involving 50 percentage points or more of the issued and
     outstanding securities of the Company.


7.   Related Party Transactions

     The Company's Director and former officer advanced funds to the Company for
     working capital needs in the amount of $ 75,248. The amounts were
     non-interest bearing, unsecured, with no stated terms or repayment.

                                       7
<PAGE>

Item 2. Management's Discussion and Analysis of Financial Condition and Results
of Operations.

FORWARD  LOOKING  STATEMENTS

Statements  contained herein which are not historical facts are forward-looking
statements  as  that term is defined by the Private Securities Litigation Reform
Act  of  1995.  Although the Company believes that the expectations reflected in
such  forward-looking  statements are reasonable, forward-looking statements are
subject  to  risks  and  uncertainties that could cause actual results to differ
from  those  projected.  The Company cautions investors that any forward-looking
statements  made  by  the  Company  are not guarantees of future performance and
actual  results  may  differ  materially  from  those  in  the  forward-looking
statements. Such risks and uncertainties include without limitation: established
competitors  who  have  substantially  greater financial resources and operating
histories,  regulatory  delays  or  denials,  ability  to  compete as a start-up
company  in  a  highly  competitive  market  and  access  to sources of capital.

The  following  discussion  and  analysis should be read in conjunction with our
financial  statements  and  notes  thereto included elsewhere in this form 10-Q.
Except  for  the historical information contained herein, the discussion in this
form  10-Q  contains  certain  forward-looking  statements that involve risk and
uncertainties,  such  as  statements  of  plans,  objectives,  expectations  and
intentions.  The  cautionary statements made in this form 10-Q should be read as
being  applicable to all related forward-looking statements wherever they appear
in  this  form  10-Q.  The Company's actual results could differ materially from
those  discussed  here.

The  Company  was  incorporated  in  the State of Nevada on June 21, 2005 and On
September  16,  2009,  the  Company changed its' name to Lightlake Therapeutics,
Inc.  The  Company's  fiscal  year  end  is  July  31 and is a development stage
Company.  Lightlake  Therapeutics  Inc.  is a drug discovery company focusing on
developing  new  and  innovative  solutions  to  obesity  and  eating disorders.

During  the  year  ended  July  31,  2009,  the company carried out very limited
operations  and  on  June  26,  2009  Belmont  Partners  (Belmont)  acquired  a
controlling interest of approximately 76.6% of the Company's outstanding shares.
(ref:  Form  8-K  filing date June 26, 2009) On July 31, 2009, the Pelikin Group
acquired  the 5,000,000 shares from Belmont and will be continuing operations as
a  pharmaceutical company focusing on developing new and innovative solutions to
obesity  and  eating  disorders.

PLAN OF OPERATION

Our plan of operation for the next twelve months is to pursue the Phase 2
clinical trials in Helsinki, Finland on the user patents that were acquired by
the company from Dr. David Sinclair, in exchange for 20,333,333 restricted
common shares on August 24, 2009.  (see Exhibit 5, Sinclair Agreement Form 10-K)
The safe and effective treatment is a proprietary patented pharmaceutical
medicine-based behaviour program pioneered by Dr. David Sinclair

We have not attained profitable operations and are dependent upon obtaining
financing to pursue the Phase 2 clinical trials in Helsinki, Finland.  For these
reasons our auditors believe that there is substantial doubt that we will be
able to continue as a going concern.

LIQUIDITY AND CAPITAL RESOURCES

Our cash reserves are not sufficient to meet our obligations for the next twelve
month  period.  As a result, we will need to seek additional funding in the near
future.  We  currently  do  not  have a specific plan of how we will obtain such
funding;  however,  we anticipate that additional funding will be in the form of
equity  financing  from the sale of our common stock. We may also seek to obtain
short-term  loans  from  our  directors, although no such arrangements have been
made.  At this time, we cannot provide investors with any assurance that we will
be  able  to  obtain  sufficient  funding  from  the sale of our common stock or
through  a  loan from our directors to meet our obligations over the next twelve
months.  We  do  not  have  any  arrangements  in  place  for  any future equity
financing.

RESULTS OF OPERATIONS

We  did  not  earn any revenues during the three month period ending October 31,
2009 and have generated no revenues since inception.  We have incurred operating
expenses  in the amount of $76,214 for the three month period ending October 31,
2009.  For  the  same  three  month period ending October 31, 2008 our operating
expense  was  $5,372.

Our net loss for the three month period ending October 31, 2009 was $76,214. Our
net loss from inception through October 31, 2009 was $131,424.

                                       8
<PAGE>

At October 31, 2009 we had assets of $21,057 and at the same date current
liabilities of $76,348.

The following table provides selected financial data about our Company as at
October 31, 2009 and July 31, 2009.

            Balance Sheet Data:            10/31/09            7/31/09
            -------------------            --------            -------

            Cash                           $    724           $    290
            Total assets                   $ 21,057           $    290
            Total Liabilities              $ 76,348           $      0
            Shareholder's equity           $ 21,057           $    290

We  have  not  attained  profitable  operations and are dependent upon obtaining
financing  to  pursue the clinical trials in Helsinki, Finland.  In their report
on  our  audited  financial  statements as at July 31, 2009, our auditors raised
substantial doubt about our ability to continue as a going concern unless we are
able  to  raise  additional  capital  and  ultimately  to  generate  profitable
operations.

SIGNIFICANT ACCOUNTING POLICIES
It  is suggested that these financial statements be read in conjunction with our
July 31, 2009 audited financial statements and notes thereto, which can be found
in  our  Form  10-K  annual filing and amendments thereto, on the SEC website at
www.sec.gov  under  our  SEC  File  Number  333-139915.

Our significant accounting policies are as follows:

PATENT OWNERSHIP

The user patents that were acquired by the company from Dr. David Sinclair, in
exchange for 20,333,333 restricted common shares on August 24, 2009.  (see
Exhibit 5, Sinclair Agreement Form 10-K) The safe and effective treatment is a
proprietary patented pharmaceutical medicine-based behaviour program pioneered
by Dr. David Sinclair.  The company plans to file and obtain the necessary
requirements to conduct Phase II clinical trials in Helsinki, Finland.  There is
no guarantee that we will obtain the approval from the Finnish authorities to
conduct the trials and the company will need to obtain the required financing if
granted the approvals to conduct the trials.  To date the company has not been
granted the approvals to conduct the trials.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

As a smaller reporting Company we are not required to provide the disclosure
required by this item.

Item 4. Controls and Procedures.

Under  the  supervision  and with the participation of our management, including
our  principal  executive  officer  and the principal financial officer, we have
conducted  an evaluation of the effectiveness of the design and operation of our
disclosure  controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e)
under  the  Securities  and  Exchange  Act  of 1934, as of the end of the period
covered  by  this  report.  Based  on  this  evaluation, our principal executive
officer and principal financial officer concluded as of the evaluation date that
our  disclosure  controls  and  procedures were effective such that the material
information  required  to  be included in our Securities and Exchange Commission
reports  is  accumulated  and  communicated  to  our  management,  including our
principal  executive  and financial officer, recorded, processed, summarized and
reported  within  the  time periods specified in SEC rules and forms relating to
our company, particularly during the period when this report was being prepared.

CHANGES  IN  INTERNAL  CONTROLS  OVER  FINANCIAL  REPORTING

There have been no changes in our internal control over financial reporting that
occurred  during  the  last  fiscal  quarter  ended  April  30,  2009  that have
materially affected, or are reasonably likely to materially affect, our internal
control  over  financial  reporting.

                                       9
<PAGE>

                          PART II - OTHER INFORMATION


ITEM 1. LEGAL PROCEEDINGS

We are not currently involved in any legal proceedings and we are not aware of
any pending or potential legal actions.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
There were no sales of unregistered securities during the period of this report.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

There were no defaults upon senior securities during the period of this report.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

There were no matters submitted to a vote of security holders during the period
covered by this report.

ITEM 5. OTHER INFORMATION

On August 5, 2009 the Company increased its authorized shares from 75,000,000 to
200,000,000.

On August 20, 2009 the Company's shares increased by a 20 for 1 split.

On September 16 2009 the Company changed its name from Madrona Ventures Inc. to
Lightlake Therapeutics Inc. and the new symbol of LLTP became effective October
7, 2009.

On October 22, 2009 the Company filed a Form 8-K/A noting the dismissal of our
former auditing firm of Dale Matheson Carr-Hilton Labonte LLP. And the
engagement of  the accounting firm of PS Stephenson & Co., P.C., CPA on August
17 2009 respectively.

On October 23, 2009 Mr. Seijin Ki resigned as his position as CEO and Dr. Roger
Crystal was appointed as the President and CEO.  This Form 8-K was filed October
23, 2009.

                                       10
<PAGE>

ITEM 6. EXHIBITS

The following exhibits are included with this quarterly filing. Those marked
with an asterisk and required to be filed hereunder, are incorporated by
reference and can be found in their entirety in our form SB-2 Registration
Statement, filed under SEC File Number 333-146934, at the SEC website at
www.sec.gov:

          Exhibit
          Number                        Description
          ------                        -----------

           3.1          Articles of Incorporation*
           3.2          Bylaws*
          31.1          Rule 13a-14(a)/14a-15(d) Certification
          31.2          Rule 13a-14(a)/14a-15(d) Certification
          32.1          Certification pursuant to 18 U.S.C. 1350
          32.2          Certification pursuant to 18 U.S.C. 1350

                                   SIGNATURES

     Pursuant  to  the  requirements of the Securities Exchange Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  thereunto  duly  authorized.


                                            LIGHTLAKE THERAPEUTICS INC.

Date: December 21, 2009                     By:  /s/ Dr. Roger Crystal
                                                 -------------------------------
                                                 Name:  Dr. Roger Crystal
                                                 Title: Chief Executive Officer
                                                        and President



Date: December 21, 2009                    By:  /s/ Seijin Ki
                                                --------------------------------
                                                Name:  Seijin Ki
                                                Title: Chief Financial Officer
                                                       and Director

                                       11